KRYS
Price
$184.22
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
109 days until earnings call
VRNA
Price
$36.93
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
105 days until earnings call
Ad is loading...

KRYS vs VRNA

Header iconKRYS vs VRNA Comparison
Open Charts KRYS vs VRNABanner chart's image
Krystal Biotech
Price$184.22
Change-$0.00 (-0.00%)
Volume$201.97K
CapitalizationN/A
Verona Pharma
Price$36.93
Change-$0.00 (-0.00%)
Volume$823.29K
CapitalizationN/A
KRYS vs VRNA Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
KRYS vs. VRNA commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and VRNA is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (KRYS: $184.22 vs. VRNA: $36.93)
Brand notoriety: KRYS and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 85% vs. VRNA: 81%
Market capitalization -- KRYS: $5.3B vs. VRNA: $3.02B
KRYS [@Biotechnology] is valued at $5.3B. VRNA’s [@Biotechnology] market capitalization is $3.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.77B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both KRYS and VRNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 5 bearish.
  • VRNA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VRNA is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а +0.62% price change this week, while VRNA (@Biotechnology) price change was -1.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +5.54%.

Reported Earning Dates

KRYS is expected to report earnings on Mar 03, 2025.

VRNA is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.3B) has a higher market cap than VRNA($3.02B). VRNA YTD gains are higher at: 85.765 vs. KRYS (48.493). KRYS has higher annual earnings (EBITDA): 181M vs. VRNA (-136.9M). KRYS has more cash in the bank: 588M vs. VRNA (336M). KRYS has less debt than VRNA: KRYS (7.48M) vs VRNA (122M). KRYS has higher revenues than VRNA: KRYS (242M) vs VRNA (5.62M).
KRYSVRNAKRYS / VRNA
Capitalization5.3B3.02B175%
EBITDA181M-136.9M-132%
Gain YTD48.49385.76557%
P/E Ratio103.49N/A-
Revenue242M5.62M4,303%
Total Cash588M336M175%
Total Debt7.48M122M6%
FUNDAMENTALS RATINGS
KRYS vs VRNA: Fundamental Ratings
KRYS
VRNA
OUTLOOK RATING
1..100
717
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
612
SMR RATING
1..100
8098
PRICE GROWTH RATING
1..100
4335
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (84) in the Pharmaceuticals Major industry is in the same range as VRNA (84) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew similarly to VRNA’s over the last 12 months.

KRYS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as VRNA (12) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew similarly to VRNA’s over the last 12 months.

KRYS's SMR Rating (80) in the Pharmaceuticals Major industry is in the same range as VRNA (98) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as KRYS (43) in the Pharmaceuticals Major industry. This means that VRNA’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as VRNA (100) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew similarly to VRNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSVRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X90584.1640002628.351600
+2.99%
Bitcoin cryptocurrency
TSLA330.241.75
+0.53%
Tesla
AAPL225.120.89
+0.40%
Apple
SPY597.190.29
+0.05%
SPDR® S&P 500® ETF Trust
GME26.46-0.38
-1.42%
GameStop Corp

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with CLDX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.60%
CLDX - KRYS
54%
Loosely correlated
-0.63%
BEAM - KRYS
46%
Loosely correlated
-1.57%
BPMC - KRYS
44%
Loosely correlated
+0.27%
RXRX - KRYS
43%
Loosely correlated
-3.43%
SNDX - KRYS
43%
Loosely correlated
+2.59%
More

VRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with KRYS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
-5.31%
KRYS - VRNA
35%
Loosely correlated
-1.60%
AKBA - VRNA
35%
Loosely correlated
-1.54%
ARQT - VRNA
34%
Loosely correlated
+2.15%
INZY - VRNA
33%
Loosely correlated
-5.59%
PLRX - VRNA
33%
Loosely correlated
-0.36%
More